An observational study in Duchene Muscular Dystrophy, sponsored by ITF Therapeutics LLC. Recruiting at 9 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by ITF Therapeutics LLC (part of Italfarmaco) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 13th largest by planned enrollment of the 55 observational ones that give a count, is one of 10 that started in 2025, is one of 55 observational ones, reaches primary completion later than 47 of the 59 other live ones, and was the 218th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 91 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 60 across 132 observational studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 172 interventional studies, 75 across the 55 observational. Of the 161 that completed or were terminated, 78 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 233 have an industry lead sponsor. The 10 most frequent:
This study is registered under ITF Therapeutics LLC, one of the names counted as Italfarmaco. Under that name alone:
This is the only study on the registry with ITF Therapeutics LLC as lead sponsor.
Italfarmaco has 8 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
18 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT05016908Massachusetts General HospitalExtracellular RNA Biomarkers of Duchenne Muscular Dystrophy | 2026-12 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.
Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that leads to progressive muscle degeneration and weakness. Givinostat, an oral histone deacetylase inhibitor, was approved by the FDA in March 2024 for treatment of DMD in patients aged 6 years and older, regardless of mutation type.
Study participation will not influence the course of treatment in any way (including other treatments for DMD), and no treatment will be provided as part of this study. All assessments are intended to be performed at the time of a routine clinical care visit according to clinical practice, and data will be extracted from the medical records.
The FDA is requiring a post-marketing prospective study be conducted for a minimum of 5 years to characterize the incidence, frequency, and severity of thrombocytopenia and serious events of bleeding in patients with DMD treated with oral givinostat in routine clinical practice.
This study is designed as a prospective, observational study to assess safety (including evaluation of AEs of special interest [AESIs]) and effectiveness, in patients with DMD newly initiating oral givinostat as part of routine clinical care in the US in a real-world population. The study will assess AESIs noted above, as well as serious adverse events (SAEs), gastrointestinal (GI) AEs, and dehydration as a sequela to GI AEs. Real-world-treatment patterns of DMD treatments (corticosteroids, exon skipping oligonucleotides and gene therapy) prior to and after givinostat initiation, including treatment duration, and treatment combinations, will be described. Effectiveness evaluations will characterize motor function, quality of life, and activities of daily living in DMD patients treated with givinostat.
The study will enroll 300 participants (180 non-ambulatory and up to 120 ambulatory patients). Participants will be followed for at least two years, with data collected during routine clinical visits. Assessments include lab parameters (e.g., platelet counts, triglycerides), cardiac and pulmonary function, patient-reported outcomes, and motor function scales such as the North Star Ambulatory Assessment (NSAA) and Performance of Upper Limb (PUL) scale.
This study will be conducted in the US and plans to enroll 300 patients diagnosed with DMD and treated with givinostat as part of their routine clinical care. Patients will be recruited from expert centers treating DMD patients with specialists in neuromuscular conditions who are routinely involved in the care and treatment of patients with DMD, some of whom would have already gained experience with givinostat.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ambulatory is defined as being able to complete the 10-meter Walk-Run (10mWR) test within 30 seconds without an assistive device. This cohort will include up to 120 patients who are ambulatory prior to starting givinostat treatment. Within this cohort , 95 patients must have had prior use or a referral for concomitant use of dystrophin-enhancing therapy (DET), such as exon skipping oligonucleotides or gene therapy. Enrollment is capped at 25 patients without prior or referred DET use.
Non-ambulatory status is determined by inability to perform the 10mWR test as defined above. This cohort will include approximately 180 patients who are non-ambulatory prior to starting givinostat.
Characterize the incidence of thrombocytopenia / decreased platelet counts in DMD patients treated with oral givinostat
Incidence rate of thrombocytopenia (per 100 patient years of observation time) post index date
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the frequency of thrombocytopenia / decreased platelet counts in DMD patients treated with oral givinostat
Frequency and incidence proportion (overall and by maximum severity) of thrombocytopenia
Time frame: [Time Frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)]
Characterize severity of serious events thrombocytopenia / decreased platelet counts in DMD patients treated with oral givinostat
Time to first thrombocytopenia event from index date
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the incidence of serious events of bleeding in DMD patients treated with oral givinostat
Incidence rate of serious bleeding events (per 100-patient years of observation time) post index date
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the frequency of serious events of bleeding in DMD patients treated with oral givinostat
Frequency and incidence proportion (overall and by maximum severity) of serious bleeding events
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the severity of serious events of bleeding in DMD patients treated with oral givinostat
Time to first serious bleeding event from index date
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the incidence of other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat
Incidence rates of each AESI (per 100-patient years of observation time) post index date as well as the incidence proportion of AESIs resulting in dose modifications or givinostat discontinuation
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the frequency other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat
Frequency and incidence proportion (overall and by maximum severity) of each AESI
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the severity of other adverse events of special interest (AESIs) in DMD patients treated with oral givinostat
Time to first event of each AESI from index date
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the incidence of all serious adverse events (SAEs) in DMD patients treated with oral givinostat
Incidence rates of SAEs (per 100-patient years of observation time) post index date by SOC and PT within SOC, and the number of SAEs per patient.
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the frequency of all serious adverse events (SAEs) in DMD patients treated with oral givinostat
Frequency and incidence proportion (overall and by maximum severity) of SAEs (by system organ class \[SOC\] and preferred term \[PT\] within SOC), and the frequency and incidence proportion of SAEs resulting in dose modifications or givinostat discontinuation.
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the incidence of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat
Incidence rates of GI AEs (per 100-patient years of observation time) post index date by PT.
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the frequency of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat
Frequency and incidence proportion (overall and by severity) of GI AEs (by PT), and frequency and incidence proportion of GI AEs resulting in dose modifications or givinostat discontinuation.
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterize the severity of gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, abdominal pain, constipation) in DMD patients treated with givinostat
Number of GI AEs per patient
Time frame: From follow up (after first date of givinostat treatment) through end of study (up to 5 years)
Characterization of hematology laboratory parameters
Change from baseline hematology laboratory parameters over time
Time frame: From baseline through end of study (up to 5 years)
Characterization of triglyceride laboratory parameters
Change from baseline triglyceride laboratory parameters over time
Time frame: From baseline through end of study (up to 5 years)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jun 2030, 56 months after the start.
Of 63 observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 120. This study's planned 56 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →